J Med Virol
. 2020 May 26.
doi: 10.1002/jmv.26063. Online ahead of print.
Compassionate Use of hzVSF-v13 in Two Patients With Severe COVID-19
Chang Kyung Kang 1 , Pyoeng Gyun Choe 1 , Sungman Park 2 , Taek Soo Kim 3 , Moon-Woo Seong 3 , Nam-Joong Kim 1 , Myoung-Don Oh 1 , Wan Beom Park 1 , Yoon-Won Kim 2
Affiliations
- PMID: 32458425
- DOI: 10.1002/jmv.26063
Abstract
We report the compassionate use of humanized Virus Suppressing Factor-variant 13 (hzVSF-v13) in two patients with severe coronavirus disease 2019 (COVID-19) pneumonia. Both patients, including an 81-year-old man who required extracorporeal membrane oxygenation, showed clinical improvement. These results warrant placebo-controlled trials to evaluate the hzVSF-v13 efficacy against COVID-19. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; antiviral agents; hzVSF-v13.